PDF(Pubmed)
Abstract：
UNASSIGNED: Few studies have reported on administering enfortumab vedotin to patients with metastatic urothelial carcinoma and end-stage renal disease requiring hemodialysis.
UNASSIGNED: Case 1: An 85-year-old man underwent hemodialysis for progressive renal failure 4 months after right laparoscopic radical nephroureterectomy. Case 2: A 73-year-old man underwent hemodialysis after two laparoscopic radical nephroureterectomies for recurrent urothelial carcinoma. In both cases, enfortumab vedotin was administered due to postoperative recurrence and progression despite platinum-based chemotherapy and pembrolizumab. Partial response and disease progression were observed in cases 1 and 2, respectively. Adverse events included a mild skin rash in both patients and neutropenia in Case 1, both of which resolved with symptomatic treatment.
UNASSIGNED: The efficacy and safety of enfortumab vedotin in patients with metastatic urothelial carcinoma, and end-stage renal disease undergoing hemodialysis, were confirmed.
UNASSIGNED: Case 1: An 85-year-old man underwent hemodialysis for progressive renal failure 4 months after right laparoscopic radical nephroureterectomy. Case 2: A 73-year-old man underwent hemodialysis after two laparoscopic radical nephroureterectomies for recurrent urothelial carcinoma. In both cases, enfortumab vedotin was administered due to postoperative recurrence and progression despite platinum-based chemotherapy and pembrolizumab. Partial response and disease progression were observed in cases 1 and 2, respectively. Adverse events included a mild skin rash in both patients and neutropenia in Case 1, both of which resolved with symptomatic treatment.
UNASSIGNED: The efficacy and safety of enfortumab vedotin in patients with metastatic urothelial carcinoma, and end-stage renal disease undergoing hemodialysis, were confirmed.
摘要：
■很少有研究报道对转移性尿路上皮癌和需要血液透析的终末期肾病患者给予enfortumabvedotin。
■案例1：一名85岁的男性在右腹腔镜肾癌根治术后4个月因进行性肾衰竭而接受血液透析。病例2：一名73岁的男子在两次腹腔镜根治性肾输尿管切除术治疗复发性尿路上皮癌后接受了血液透析。在这两种情况下，尽管进行了铂类药物化疗和派姆单抗治疗,但由于术后复发和进展,因此给予enfortumabvedotin.分别在病例1和2中观察到部分反应和疾病进展。不良事件包括两个患者的轻度皮疹和病例1的中性粒细胞减少，两者均通过对症治疗解决。
■enfortumabvedotin对转移性尿路上皮癌患者的疗效和安全性，接受血液透析的终末期肾病，得到确认。
■案例1：一名85岁的男性在右腹腔镜肾癌根治术后4个月因进行性肾衰竭而接受血液透析。病例2：一名73岁的男子在两次腹腔镜根治性肾输尿管切除术治疗复发性尿路上皮癌后接受了血液透析。在这两种情况下，尽管进行了铂类药物化疗和派姆单抗治疗,但由于术后复发和进展,因此给予enfortumabvedotin.分别在病例1和2中观察到部分反应和疾病进展。不良事件包括两个患者的轻度皮疹和病例1的中性粒细胞减少，两者均通过对症治疗解决。
■enfortumabvedotin对转移性尿路上皮癌患者的疗效和安全性，接受血液透析的终末期肾病，得到确认。
